A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)
Status:
Not yet recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety,
pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or
refractory cluster of differentiation (CD)19-positive B-cell malignancies.